[1]
|
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi: 10.3322/caac.21660 |
[2]
|
Chen F, Wendl MC, Wyczalkowski MA, et al. Moving pan-cancer studies from basic research toward the clinic[J]. Nat Cancer, 2021, 2: 879-890. doi: 10.1038/s43018-021-00250-4 |
[3]
|
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10: 459-466. doi: 10.1016/S1470-2045(09)70025-7 |
[4]
|
Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial[J]. JAMA, 2017, 318: 2306-2316. doi: 10.1001/jama.2017.18718 |
[5]
|
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neuro Oncol, 2021, 23: 1231-1251. doi: 10.1093/neuonc/noab106 |
[6]
|
Wong QH, Li KK, Wang WW, et al. Molecular landscape of IDH-mutant primary astrocytoma Grade Ⅳ/glioblastomas[J]. Mod Pathol, 2021, 34: 1245-1260. doi: 10.1038/s41379-021-00778-x |
[7]
|
Jin L, Shi F, Chun Q, et al. Artificial intelligence neuropathologist for glioma classification using deep learning on hematoxylin and eosin stained slide images and molecular markers[J]. Neuro Oncol, 2021, 23: 44-52. doi: 10.1093/neuonc/noaa163 |
[8]
|
Wen PY, Packer RJ. The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications[J]. Neuro Oncol, 2021, 23: 1215-1217. doi: 10.1093/neuonc/noab120 |
[9]
|
Mohile NA, Messersmith H, Gatson NT, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline[J]. J Clin Oncol, 2022, 40: 403-426. |
[10]
|
Jiang T, Nam DH, Ram Z, et al. Clinical practice guidelines for the management of adult diffuse gliomas[J]. Cancer Lett, 2021, 499: 60-72. doi: 10.1016/j.canlet.2020.10.050 |
[11]
|
Gao A, Zhang H, Yan X, et al. Whole-Tumor Histogram Analysis of Multiple Diffusion Metrics for Glioma Genotyping[J]. Radiology, 2022, 302: 652-661. doi: 10.1148/radiol.210820 |
[12]
|
Sun Q, Chen Y, Liang C, et al. Biologic Pathways Underlying Prognostic Radiomics Phenotypes from Paired MRI and RNA Sequencing in Glioblastoma[J]. Radiology, 2021, 301: 654-663. doi: 10.1148/radiol.2021203281 |
[13]
|
Xie R, Wu Z, Zeng F, et al. Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glio-blastoma[J]. Signal Transduct Target Ther, 2021, 6: 309. doi: 10.1038/s41392-021-00724-y |
[14]
|
Yang J, Zhao C, Lim J, et al. Structurally symmetric near-infrared fluorophore IRDye78-protein complex enables multimodal cancer imaging[J]. Theranostics, 2021, 11: 2534-2549. doi: 10.7150/thno.54928 |
[15]
|
Li Z, Kong Z, Chen J, et al. (18)F-Boramino acid PET/CT in healthy volunteers and glioma patients[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 3113-3121. doi: 10.1007/s00259-021-05212-7 |
[16]
|
Zhang Y, Xi K, Fu X, et al. Versatile metal-phenolic network nanoparticles for multitargeted combination therapy and magnetic resonance tracing in glioblastoma[J]. Biomaterials, 2021, 278: 121163. doi: 10.1016/j.biomaterials.2021.121163 |
[17]
|
Huang N, Li F, Zhang M, et al. An Upstream Open Reading Frame in Phosphatase and Tensin Homolog Encodes a Circuit Breaker of Lactate Metabolism[J]. Cell Metab, 2021, 33: 128-144. e9. doi: 10.1016/j.cmet.2020.12.008 |
[18]
|
Wu X, Xiao S, Zhang M, et al. A novel protein encoded by circular SMO RNA is essential for Hedgehog signaling activation and glioblastoma tumorigenicity[J]. Genome Biol, 2021, 22: 33. doi: 10.1186/s13059-020-02250-6 |
[19]
|
Wang X, Zhou R, Xiong Y, et al. Sequential fate-switches in stem-like cells drive the tumorigenic trajectory from human neural stem cells to malignant glioma[J]. Cell Res, 2021, 31: 684-702. doi: 10.1038/s41422-020-00451-z |
[20]
|
中国医师协会脑胶质瘤专业委员会, 中国抗癌协会脑胶质瘤专业委员会, 中国脑胶质瘤协作组. 成人丘脑胶质瘤手术治疗中国专家共识[J]. 临床神经外科杂志, 2022, 19: 1-10. doi: 10.3969/j.issn.1672-7770.2022.01.001
Society for NeuroOncology of China, Chinese Anti-Cancer Association Committee of the Glioma, Chinese Glioma Cooperative Group. Chinese experts consensus on surgical treatment for adult thalamus glioma[J]. Linchuang Shenjing Waike Zazhi, 2022, 19: 1-10. doi: 10.3969/j.issn.1672-7770.2022.01.001 |
[21]
|
Niu X, Yang Y, Zhou X, et al. A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort[J]. Neuro Oncol, 2021, 23: 337-338. doi: 10.1093/neuonc/noaa268 |
[22]
|
Hou Z, Zhang K, Liu X, et al. Molecular subtype impacts surgical resection in low-grade gliomas: A Chinese Glioma Genome Atlas database analysis[J]. Cancer Lett, 2021, 522: 14-21. doi: 10.1016/j.canlet.2021.09.008 |
[23]
|
Lu J, Zhao Z, Zhang J, et al. Functional maps of direct electrical stimulation-induced speech arrest and anomia: a multicentre retrospective study[J]. Brain, 2021, 144: 2541-2553. doi: 10.1093/brain/awab125 |
[24]
|
Sun R, Cuthbert H, Watts C. Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future[J]. Cancers (Basel), 2021, 13: 3508. doi: 10.3390/cancers13143508 |
[25]
|
Gao XY, Zang J, Zheng MH, et al. Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma[J]. Front Cell Dev Biol, 2021, 9: 620883. doi: 10.3389/fcell.2021.620883 |
[26]
|
Zheng Y, Liu L, Wang Y, et al. Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma[J]. Cell Biosci, 2021, 11: 63. doi: 10.1186/s13578-021-00575-8 |
[27]
|
Wang Z, Wang Y, Yang T, et al. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients[J]. Brief Bioinform, 2021, 22: bbab032. doi: 10.1093/bib/bbab032 |
[28]
|
Li J, Kaneda MM, Ma J, et al. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response[J]. Proc Natl Acad Sci U S A, 2021, 118: e2009290118. doi: 10.1073/pnas.2009290118 |
[29]
|
Li Z, Meng X, Wu P, et al. Glioblastoma Cell-Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance[J]. Cancer Immunol Res, 2021, 9: 1383-1399. doi: 10.1158/2326-6066.CIR-21-0258 |
[30]
|
Zhang XN, Yang KD, Chen C, et al. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling[J]. Cell Res, 2021, 31: 1072-1087. doi: 10.1038/s41422-021-00528-3 |
[31]
|
Oldrini B, Vaquero-Siguero N, Mu Q, et al. MGMT genomic rearrangements contribute to chemotherapy resis-tance in gliomas[J]. Nat Commun, 2020, 11: 3883. doi: 10.1038/s41467-020-17717-0 |
[32]
|
Shi J, Chen G, Dong X, et al. METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner[J]. Front Oncol, 2021, 11: 702983. doi: 10.3389/fonc.2021.702983 |
[33]
|
Li F, Chen S, Yu J, et al. Interplay of m6 A and histone modifications contributes to temozolomide resistance in glioblastoma[J]. Clin Transl Med, 2021, 11: e553. |
[34]
|
Yuan Q, Yang W, Zhang S, et al. Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma[J]. Mol Med, 2021, 27: 7. |
[35]
|
Yang W, Yuan Q, Zhang S, et al. Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma[J]. Cancer Gene Ther, 2022, 29: 750-757. doi: 10.1038/s41417-021-00353-1 |
[36]
|
Wang K, Kievit FM, Chiarelli PA, et al. siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model[J]. Adv Funct Mater, 2021, 31: 2007166. doi: 10.1002/adfm.202007166 |
[37]
|
Yang Q, Zhou Y, Chen J, et al. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanopar-ticles Combined with Focused Ultrasound[J]. Int J Nanomedicine, 2021, 16: 185-199. doi: 10.2147/IJN.S286221 |
[38]
|
Liu Y, Bao Q, Chen Z, et al. Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method[J]. Nano Lett, 2021, 21: 9115-9123. doi: 10.1021/acs.nanolett.1c02803 |
[39]
|
Hu H, Mu Q, Bao Z, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor[J]. Cell, 2018, 175: 1665-1678. e1618. doi: 10.1016/j.cell.2018.09.038 |
[40]
|
Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial[J]. Lancet Oncol, 2022, 23: 53-64. doi: 10.1016/S1470-2045(21)00578-7 |
[41]
|
Yang Q, Guo C, Lin X, et al. Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis[J]. Front Pharmacol, 2021, 12: 804942. doi: 10.3389/fphar.2021.804942 |
[42]
|
Lombardi G, De Salvo GL, Brandes AA, et al. Regora-fenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2019, 20: 110-119. doi: 10.1016/S1470-2045(18)30675-2 |
[43]
|
Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma[J]. Nat Rev Clin Oncol, 2018, 15: 422-442. doi: 10.1038/s41571-018-0003-5 |
[44]
|
Fares J, Ahmed AU, Ulasov IV, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial[J]. Lancet Oncol, 2021, 22: 1103-1114. doi: 10.1016/S1470-2045(21)00245-X |
[45]
|
Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis[J]. Nat Med, 2021, 27: 1544-1552. doi: 10.1038/s41591-021-01404-8 |
[46]
|
Gao X, Xia X, Li F, et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigeni-city through activation of EGFR-STAT3 signalling[J]. Nat Cell Biol, 2021, 23: 278-291. doi: 10.1038/s41556-021-00639-4 |
[47]
|
Hasan MN, Luo L, Ding D, et al. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells[J]. Theranostics, 2021, 11: 1295-1309. doi: 10.7150/thno.50150 |
[48]
|
Chen Q, Jin J, Huang X, et al. EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion[J]. J Exp Clin Cancer Res, 2021, 40: 160. doi: 10.1186/s13046-021-01954-2 |
[49]
|
Wang QW, Sun LH, Zhang Y, et al. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas[J]. J Immunother Cancer, 2021, 9: e002451. doi: 10.1136/jitc-2021-002451 |
[50]
|
Amoozgar Z, Kloepper J, Ren J, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas[J]. Nat Commun, 2021, 12: 2582. doi: 10.1038/s41467-021-22885-8 |
[51]
|
Cao Y, Ding S, Zeng L, et al. Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy[J]. ACS Appl Mater Interfaces, 2021, 13: 53504-53518. doi: 10.1021/acsami.1c07626 |
[52]
|
Fan Y, Cui Y, Hao W, et al. Carrier-free highly drug-loaded biomimetic nanosuspensions encapsulated by cancer cell membrane based on homology and active targeting for the treatment of glioma[J]. Bioact Mater, 2021, 6: 4402-4414. doi: 10.1016/j.bioactmat.2021.04.027 |
[53]
|
Wang Y, Jiang Y, Wei D, et al. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance[J]. Nat Biomed Eng, 2021, 5: 1048-1058. doi: 10.1038/s41551-021-00728-7 |
[54]
|
Miao YB, Chen KH, Chen CT, et al. A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors[J]. Adv Mater, 2021, 33: e2100701. doi: 10.1002/adma.202100701 |
[55]
|
Wang J, Tang W, Yang M, et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy[J]. Biomaterials, 2021, 273: 120784. doi: 10.1016/j.biomaterials.2021.120784 |
[56]
|
Zhang J, Chen C, Li A, et al. Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection[J]. Nat Nanotechnol, 2021, 16: 538-548. doi: 10.1038/s41565-020-00843-7 |
[57]
|
Niu W, Xiao Q, Wang X, et al. A Biomimetic Drug Delivery System by Integrating Grapefruit Extracellular Vesicles and Doxorubicin-Loaded Heparin-Based Nanoparticles for Glioma Therapy[J]. Nano Lett, 2021, 21: 1484-1492. doi: 10.1021/acs.nanolett.0c04753 |
[58]
|
Liu Y, Wang X, Li J, et al. Sphingosine 1-Phosphate Liposomes for Targeted Nitric Oxide Delivery to Mediate Anticancer Effects against Brain Glioma Tumors[J]. Adv Mater, 2021, 33: e2101701. doi: 10.1002/adma.202101701 |